There is a move towards personalised medicines particularly in the treatment of unmet medical needs, however, currently available dosage forms and manufacturing procedures are not suited for the manufacture of personalised medicine. Our research is focused on the use of cutting-edge pharmaceutical engineering technologies such as hot melt extrusion, injection moulding, 3D printing, microfluidics etc. to manufacture novel implantable drug delivery devices and nanoparticles for the localised and personalised treatment of cancers.
This research has resulted in the development of an implantable drug delivery device (ChemoSeed®) for the local delivery of personalised chemotherapy regimens to the brain to treat brain tumours as well as a device for the delayed and localised delivery of personalised chemotherapy to the pancreatic cancer margin (ChemoPatch). The group spun ChemoSeed out as a company, Extruded Pharmaceuticals Ltd, to raise the investment needed to technology transfer to a GMP compliant CDMO and complete a Phase II registration grade clinical trial in high-grade glioma patents.
Extruded Pharmaceuticals Ltd underwent an Initial Public Offering on the London Stock Exchange (LSE) Alternative Investments Market (AIM) becoming CRISM Therapeutics Corporation. Extruded Pharmaceuticals Ltd went on to take ChemoSeed® into the clinic and onto commercialisation. ChemoSeed® is currently being utilised by several pharmaceutical companies for the sustained delivery of their leading drug candidates.